In contrast to typical sirtuin inhibition modes, the recommended Sirt6 inhibitor, JYQ-42 [165], allosterically decreases Sirt6 deacetylase activity and demonstrates translational promise in pancreatic cancer cell models. Here, SIRT6 is linked to pancreatic neoplasm.